Diagnostics (Mar 2023)

Performance of VIDAS<sup>®</sup> Diagnostic Tests for the Automated Detection of Dengue Virus NS1 Antigen and of Anti-Dengue Virus IgM and IgG Antibodies: A Multicentre, International Study

  • Alice F. Versiani,
  • Antoinette Kaboré,
  • Ludovic Brossault,
  • Loïc Dromenq,
  • Thayza M. I. L. dos Santos,
  • Bruno H. G. A. Milhim,
  • Cássia F. Estofolete,
  • Assana Cissé,
  • Pegdwendé Abel Sorgho,
  • Florence Senot,
  • Marie Tessonneau,
  • Serge Diagbouga,
  • Mauricio L. Nogueira

DOI
https://doi.org/10.3390/diagnostics13061137
Journal volume & issue
Vol. 13, no. 6
p. 1137

Abstract

Read online

Dengue is a serious mosquito-transmitted disease caused by the dengue virus (DENV). Rapid and reliable diagnosis of DENV infection is urgently needed in dengue-endemic regions. We describe here the performance evaluation of the CE-marked VIDAS® dengue immunoassays developed for the automated detection of DENV NS1 antigen and anti-DENV IgM and IgG antibodies. A multicenter concordance study was conducted in 1296 patients from dengue-endemic regions in Asia, Latin America, and Africa. VIDAS® dengue results were compared to those of competitor enzyme-linked immunosorbent assays (ELISA). The VIDAS® dengue assays showed high precision (CV ≤ 10.7%) and limited cross-reactivity (≤15.4%) with other infections. VIDAS® DENGUE NS1 Ag showed high positive and negative percent agreement (92.8% PPA and 91.7% NPA) in acute patients within 0–5 days of symptom onset. VIDAS® Anti-DENGUE IgM and IgG showed a moderate-to-high concordance with ELISA (74.8% to 90.6%) in post-acute and recovery patients. PPA was further improved in combined VIDAS® NS1/IgM (96.4% in 0–5 days acute patients) and IgM/IgG (91.9% in post-acute patients) tests. Altogether, the VIDAS® dengue NS1, IgM, and IgG assays performed well, either alone or in combination, and should be suitable for the accurate diagnosis of DENV infection in dengue-endemic regions.

Keywords